At the different phases of clinicopathological staging, we observed that PABPC1 expression in patients with PAAD with a high TNM stage (stage IV) was marginally enhanced compared with that in the patients with a low tumor stage (stage I, II, and III) (Figure 1C). Here, PABPC1 is linked to pancreatic adenocarcinoma.